成人急性淋巴细胞白血病:2025年诊断、治疗与监测更新
该综述概述成人急性淋巴细胞白血病(ALL)的诊断、治疗与监测进展。2024年美国约诊断6500例新发ALL;多药化疗2-3年使儿童长期生存达80%-90%,成人仅40%-50%。费城染色体阳性B细胞ALL采用TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上;费城染色体阴性B细胞ALL将奥加伊妥珠单抗和贝林妥欧单抗纳入方案;T细胞ALL采用含聚乙二醇门冬酰胺酶和奈拉滨的联合化疗。
要点
- 费城染色体阳性B细胞ALL采用TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上。
- 费城染色体阴性B细胞ALL将奥加伊妥珠单抗和贝林妥欧单抗纳入化疗方案以提高MRD阴性率和长期结局。
- T细胞ALL采用含聚乙二醇门冬酰胺酶和奈拉滨的联合化疗,早期T细胞前体ALL应考虑异基因干细胞移植。
核心结论
- 费城染色体阳性B细胞ALL采用TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上;达到完全分子学缓解可能识别可避免异基因干细胞移植的患者。
- 费城染色体阴性B细胞ALL将奥加伊妥珠单抗和贝林妥欧单抗纳入化疗方案以提高可测量残留病阴性率和长期结局,能接受这些治疗的患者4年生存率提高至80%-85%。
- ≥60岁老年患者使用奥加伊妥珠单抗和贝林妥欧单抗替代强化化疗改善了安全性和疗效。
- T细胞ALL采用含聚乙二醇门冬酰胺酶和奈拉滨的联合化疗;早期T细胞前体ALL为高危亚组,应考虑异基因干细胞移植。
- 挽救治疗中单药获批,但化疗和免疫治疗联合后行CAR T细胞巩固和异基因干细胞移植获得最佳结局。
研究设计与样本
- 该文为成人急性淋巴细胞白血病2025年诊断、治疗与监测更新综述,未报告系统检索范围。
主要发现
- 2024年美国约诊断6500例新发ALL;多药化疗2-3年使儿童长期生存达80%-90%,成人仅40%-50%,取决于患者和疾病特征。
- 费城染色体阳性B细胞ALL采用TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上。
- 经免疫化疗方案治疗,能接受这些治疗的患者4年生存率提高至80%-85%。
- ≥60岁老年患者使用奥加伊妥珠单抗和贝林妥欧单抗替代强化化疗改善了安全性和疗效。
- 早期T细胞前体ALL为高危亚组,应考虑异基因干细胞移植;将BCL-2抑制剂维奈克拉纳入治疗可能有益,目前正在研究中。
关键数值与推荐
- 费城染色体阳性B细胞ALL:TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上。
- 费城染色体阴性B细胞ALL:将奥加伊妥珠单抗和贝林妥欧单抗纳入化疗方案,能接受这些治疗的患者4年生存率80%-85%。
- ≥60岁老年患者:使用奥加伊妥珠单抗和贝林妥欧单抗替代强化化疗。
- T细胞ALL:含聚乙二醇门冬酰胺酶和奈拉滨的联合化疗;早期T细胞前体ALL应考虑异基因干细胞移植。
- 挽救治疗:化疗和免疫治疗联合后行CAR T细胞巩固和异基因干细胞移植获得最佳结局。
临床怎么用
- 费城染色体阳性B细胞ALL采用TKI联合多药化疗或贝林妥欧单抗,5年生存率80%以上。
- 费城染色体阴性B细胞ALL将奥加伊妥珠单抗和贝林妥欧单抗纳入化疗方案以提高可测量残留病阴性率和长期结局。
- ≥60岁老年患者使用奥加伊妥珠单抗和贝林妥欧单抗替代强化化疗以改善安全性和疗效。
- 早期T细胞前体ALL应考虑异基因干细胞移植;维奈克拉纳入治疗可能有益,目前正在研究中。
- 挽救治疗中化疗和免疫治疗联合后行CAR T细胞巩固和异基因干细胞移植获得最佳结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Acute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells arising in the bone marrow and extramedullary sites. While it is the most common pediatric cancer, ALL is a rare disease overall, with approximately 6500 new cases diagnosed in the United States, in 2024. Current treatment relies on multiagent chemotherapy administered over 2-3 years, resulting in long-term survival in 80%-90% in pediatric patients compared to 40%-50% in adult patients, depending upon patient- and disease-specific characteristics. PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ALL: Historically considered a poor risk ALL subtype, the treatment and outcome of Philadelphia chromosome (Ph)-positive B-cell ALL were drastically changed with the advent of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The combination of a TKI with a backbone of multiagent chemotherapy, or more recently blinatumomab, is the mainstay of therapy, resulting in 5-year survival rates of 80+%. Achieving a complete molecular remission, particularly by next generation sequencing, is an important prognostic indicator, which may identify patients who may avoid allogeneic stem cell transplantation (SCT). PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ALL: The treatment approach for patients with Ph-negative B-cell ALL was historically composed of a chemotherapy backbone (either pediatric-inspired, or Hyper-CVAD based). Novel agents including inotuzumab ozogamicin and blinatumomab are being incorporated into these regimens to improve the rates of measurable residual disease negativity and long-term outcomes. While differences in long-term survival rates differ between age groups, such as adolescents and young adults compared to older adults (≥ 60 years), with these immunotherapy-chemotherapy regimens, the 4-year survival rates have improved to 80%-85% among patients who are able to receive these treatments. Elderly patients represent a difficult population to treat due to poor chemotherapy tolerance, high-risk disease features, and increased risk of developing therapy-related myeloid neoplasms. The use of inotuzumab ozogamicin and blinatumomab in lieu of intensive chemotherapy in this population has improved safety and efficacy in patients ≥ 60 years old. Clinical trials incorporating chimeric antigen receptor (CAR) T-cell therapy into treatment for older patients are in progress. T-CELL ALL: Combination chemotherapy regimens incorporating pegylated asparaginase and nelarabine are the standard for patients with T-cell ALL. Early T-cell precursor (ETP) ALL is a high-risk subgroup for which allogeneic SCT should be considered. Inclusion of the BCL-2 inhibitor venetoclax into treatment for patients with ETP-ALL may be beneficial and is currently being investigated. SALVAGE THERAPY: Several therapies are approved as single agents in the salvage setting. However, the best outcomes are obtained with combination therapy including chemo- and immuno- therapies followed by CAR T-cell consolidation and allogeneic SCT. Clinical trials optimizing this approach are ongoing.
引用
- Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol. 2025. PMID: 40377367. doi:10.1002/ajh.27708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。